111 results
DEFA14A
KPRX
Kiora Pharmaceuticals Inc
29 Apr 20
Additional proxy soliciting materials
4:16pm
. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side). We encourage you to access and review … to Access the Proxy Materials Proxy Materials Available to VIEW or RECEIVE: How to View Online: Have the information that is printed in the box marked
DEFA14A
KPRX
Kiora Pharmaceuticals Inc
2 May 19
Additional proxy soliciting materials
7:38am
. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side). We encourage you to access and review … to Access the Proxy Materials Proxy Materials Available to VIEW or RECEIVE: How to View Online: Have the information that is printed in the box marked
DEFA14A
KPRX
Kiora Pharmaceuticals Inc
29 May 18
Additional proxy soliciting materials
4:32pm
may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).We encourage you to access and review all … , Massachusetts 02110
Before You Vote How to Access the Proxy Materials Please Choose One of the Following Voting Methods Vote In Person: Many
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
in near-term milestones Kiora would have owed to Sentrx
Sentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 … structure benefits both companies. It provides us with greater financial flexibility to invest in our development pipeline, and offers Sentrx access
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
and access to resources as such Party ("Comparator Company") in respect of a product of similar market potential, at a similar stage in its development … the legal authority or right (whether by ownership, license or otherwise) to grant a license, sublicense, access or right to use (as applicable) under
8-K
EX-99.2
f88xpkw9f21zz
13 Nov 18
Eyegate Pharma Announces Positive Results In Second PRK Study
7:00am
8-K
2zz8fslb
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
hw62so6g j6ny
27 Apr 23
Other Events
2:55pm
8-K
EX-99.1
wo6gupc
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
7t06r303hpc8s9n7tp
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K
EX-99.1
jmzu6p7p kn0hc1dba
27 May 21
Regulation FD Disclosure
7:01am
8-K
EX-99.1
eeipqeq719rz pde9
6 Nov 23
Topline Phase I/II First-in-Human Results Presented at AAO 2023
6:05am
424B3
qht uex7izkmxvp
28 Dec 22
Prospectus supplement
4:48pm
8-K
EX-99.2
d7ir2xapk0uq72jj7
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-10.2
lbaqpwh
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm